FDA Approves Gene Therapy for Glycogen Storage Disease Type 1a

The FDA has approved the first gene therapy for treating Glycogen Storage Disease Type 1a, a rare genetic disorder. This approval introduces a new regulatory pathway and treatment option in genetic medicine.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 19 Aug 2026 and 22 Aug 2026.